Streetbeat News

Stock Prices

CTRI

In the last three months, analysts have shown a bearish sentiment towards Centuri Holdings (NYSE:CTRI), with recent ratings indicating a decline in price targets. The company's financial performance is challenged by declining revenue, low net margins, and high debt levels.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 2:00 pm

AJG

Arthur J. Gallagher (NYSE:AJG) has outperformed the market over the past 20 years with an average annual return of 11.86%, surpassing the market by 3.3% annually. A $100 investment in AJG 20 years ago would now be worth $869.09.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 2:00 pm

DHI

D.R. Horton (NYSE:DHI) has significantly outperformed the market over the past 5 years, with an average annual return of 28.69%. A $1000 investment in DHI 5 years ago would now be worth $3,495.05, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 2:00 pm

DVA

Analysts have recently updated their ratings on DaVita (NYSE:DVA), with a mix of bullish and bearish perspectives. The average 12-month price target has increased by 6.3% to $162.0. DaVita, a leading dialysis service provider, shows strong financial metrics but has a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 2:00 pm

COR

In the past three months, analysts have provided mixed ratings for Cencora (NYSE:COR), with most being somewhat bullish. The average 12-month price target has slightly decreased to $271.0. Cencora, a leading pharmaceutical wholesaler, shows strong financials with impressive revenue growth and profitability, but carries a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 2:00 pm

HAO

Haoxi Health Technology shares are trading lower following the announcement of their preliminary FY24 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 1:59 pm

XPON

Expion360 shares declined following the announcement of a 1-for-100 reverse stock split, which typically reduces the number of shares outstanding and can impact stock price perception.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 1:58 pm

LLY

NVO

REGN

Regeneron's Chief Scientific Officer, George Yancopoulos, has raised concerns about the health risks of GLP-1 weight-loss drugs like Ozempic, citing rapid muscle loss as a significant issue. Regeneron is developing muscle-preserving treatments to address this, including a Phase 2 trial for trevogrumab. Eli Lilly has also entered the obesity drug market with its acquisition of Versanis Bio.

Portfolio Pulse from Vandana Singh

October 07, 2024 | 1:57 pm

CPNG

Coupang shares rise as Bernstein upgrades the stock from Underperform to Outperform.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 1:54 pm

PFE

Pfizer shares are experiencing an uptick following the acquisition of a $1 billion stake by Starboard Value, indicating increased investor confidence.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 1:52 pm